The values of urinary NTx in postmenopausal women undergoing HRT; the role of additional alendronate therapy

Maturitas

Volumn 42, Issue 4, 2002, Pages 281-286

  Posaci, Cemal ^a   Altunyurt, Sabahattin ^a   Islekel, Huray ^a   Saygili, Ugur ^a   Altekin, Emel ^a   Onvural, Ata ^a   Onvural, Banu ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Alendronate; Hormone replacement therapy; NTx

Indexed keywords

ALENDRONIC ACID; ESTRADIOL PLUS NORETHISTERONE ACETATE;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; URINARY EXCRETION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; ALENDRONATE; BONE DENSITY; COLLAGEN; COLLAGEN TYPE I; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; NORETHINDRONE; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; POSTMENOPAUSE; PROSPECTIVE STUDIES;

EID: 0037199739     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(02)00156-1     Document Type: Article

References (24)

1. Maintenance of bone mass
2. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine
3. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment
4. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine
5. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy
6. The effect of hormone replacement therapy in postmenopausal women on urinary C-telopeptide and N-telopeptide of type 1 collagen, new markers of bone resorption
7. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation
8. Alendronate treatment for osteoporosis: A review of the clinical evidence
9. Treatment of generalized osteoporosis with inhibitors of bone resorption
10. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women
11. Changes in urinary excretion of type-I collagen cross-linked C-telopeptide and N-telopeptide in perimenopausal women
12. Biochemical markers of bone turnover during hormone replacement therapy
13. Changes in bone collagen markers and in bone density in hormone treated and untreated postmenopausal women
14. Bone resorption levels by age and menopausal status in 5,157 women
15. The short-term effects of conjugated estrogen on bone turnover in older women
16. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion
17. Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density
18. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: Result from the postmenopausal estrogen-progestin interventions (PEPI) trial
19. Bone mineral density and biochemical markers of bone turnover in peri- and postmenopausal women
20. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men
21. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial
22. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: A prospective, randomized study
23. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women
24. Clinical usefulness of biochemical resorption markers in osteoporosis